Upperton Unveils New Brand Identity for End-to-End CDMO
Upperton has unveiled a new brand identity at CPHI Milan as it positions itself as a specialist, end-to-end contract development and manufacturing organization (CDMO) focused
Ofichem to Acquire Kinentia Biosciences and Expand Into U.S. Market
Ofichem has signed an agreement to acquire Kinentia Biosciences, a Drug Substance CDMO based in Rensselaer, New York. Completion of the transaction remains subject to
RoslinCT Receives Up to £7.25M Grant for Digital Manufacturing Expansion
RoslinCT, a cell therapy Contract Development and Manufacturing Organization (CDMO), has been awarded an R&D grant from Scottish Enterprise to accelerate the digital transformation of
Piramal Pharma Solutions Adds Microbiology Capacity at Kentucky Sterile Facility
Piramal Pharma Solutions (PPS) has opened a new microbiology laboratory at its sterile injectable facility in Lexington, Kentucky, as part of its ongoing $85 million
Genezen Partners With InterAct Therapeutics on AAV8 Cancer Gene Therapy
Genezen, a gene therapy contract development and manufacturing organization (CDMO), has entered into a strategic manufacturing partnership with InterAct Therapeutics to advance the clinical development
Curia Invests $28 Million in Sterile API Manufacturing
Curia Global, Inc. (Curia), a contract development and manufacturing organization (CDMO), is making a strategic investment to expand sterile API manufacturing capabilities at its Valladolid,
MedPharm Signs Commercial Manufacturing Agreement With Global Pharmaceutical Company
MedPharm, a contract drug development and manufacturing organization focused on topical and transdermal products, has signed an agreement with a global pharmaceutical company to support
Catalent Launches 10-Month Gene-to-Drug Substance Program for Complex Biologics
Catalent, a global contract development and manufacturing organization (CDMO), has launched a U.S. accelerated gene-to-drug substance program for complex biologics. The program is designed to
GE HealthCare to Acquire SOFIE Biosciences for $945 Million
GE HealthCare has entered into a definitive agreement to acquire SOFIE Biosciences, a U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America for $945 million
Flamma Acquires Lundbeck API Site in Italy
Flamma, a Contract Development and Manufacturing Organization (CDMO) focused on small molecule APIs, peptides and advanced intermediates, has entered into an agreement to acquire Lundbeck